SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EARNINGS FLASH L impact

Dyne Therapeutics Reports Wider Net Loss in Third Quarter

The company said higher research and development and general and administrative expenses contributed to the wider year-over-year net loss. The headline lists EPS of ($1.06).

DYN

Related stories